article thumbnail

UK biotech sees worst funding downturn since 2012

pharmaphorum

Indeed, Initial Public Offerings (IPOs) raised just £28 million – the worst annual haul since 2012 – and, during the entirety of last year, UK biotech raised just £1.8 There is global capital out there for us to attract, as well as finance in the City of London [that] we need to unlock, but competition is fierce.” billion in 2021.

Pharma 52
article thumbnail

Pfizer, Flynn fined £70m in resurrected epilepsy drug pricing probe

pharmaphorum

Drugmakers Pfizer and Flynn Pharma have been fined £70 million ($84 million) by the UK Competition and Markets Authority (CMA) for overcharging the NHS for a widely-used epilepsy drug. ” The post Pfizer, Flynn fined £70m in resurrected epilepsy drug pricing probe appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pfizer and Flynn appeal £70m epilepsy drug fines in UK

pharmaphorum

Drugmakers Pfizer and Flynn Pharma have formally launched an appeal against a £70 million ($84 million) fine levied by the UK Competition and Markets Authority (CMA) for overcharging the NHS for a widely-used epilepsy drug. The CAT typically takes around nine months to deliver a verdict, although it can take longer in more complicated cases.

article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4 Lane S, Lynn E, Shakir S.

Safety 112
article thumbnail

Eczac?ba?? to acquire Turkish pharma company Gensenta for $135m

Pharmaceutical Technology

In 2012, the company was acquired by Amgen and renamed Gensenta in 2020. The acquisition of Gensenta will be completed on obtaining the Turkish Competition Authority approval. Amgen Turkey noted that the company will maintain its operations and serve its patients in the region. board chairperson Bülent Eczac?ba??

Pharma 59
article thumbnail

NICE unlocks use of Amarin’s Vazkepa in 425k NHS patients

pharmaphorum

Amarin first introduced its drug in the US as Vascepa in 2012, but only made it available in Europe last year, starting with a German launch last September. .” NHS England has estimated that between 25% and 35% of people having statin therapy have elevated triglycerides.

article thumbnail

Briumvi may struggle to make headway in crowded multiple sclerosis market

Pharmaceutical Technology

Competitive pricing will therefore be essential if the drug is to compete effectively in the MS market and gain a significant patient share. This is despite the fact that Briumvi needs half the infusion time per patient visit in comparison to Ocrevus.